Drug intelligence / Profile preview

CTN002

Development stage: Preclinical
Lead developer: Centenaire Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CTN002 is a monoclonal antibody developed by Centenaire Biosciences for the treatment of hepatocellular carcinoma (HCC). It is engineered using the company's proprietary Twin Fc-ICE (Immune Cell Engagement) technology platform, which involves a restructured monoclonal antibody designed to enhance immune cell engagement and effector functions. CTN002 specifically targets Glypican-3 (GPC3), a cell-surface oncofetal antigen that is highly expressed in HCC but has limited expression in normal adult tissues. By binding to GPC3, CTN002 aims to selectively engage immune effector cells to eliminate cancer cells. As of early 2024, the drug is in the preclinical stage of development.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on CTN002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN002.

Explore the full profile